These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37912644)

  • 1. Influences That Retard Evolution in Dental Science.
    Palmer SB
    Int Dent J (Phila); 1900 Feb; 21(2):84-101. PubMed ID: 37912644
    [No Abstract]   [Full Text] [Related]  

  • 2. The influence of "new science" on dental education: current concepts, trends, and models for the future.
    Iacopino AM
    J Dent Educ; 2007 Apr; 71(4):450-62. PubMed ID: 17468305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics and pharmacokinetics of furosemide-retard and furosemide-retard/triamterene.
    Heimsoth V; Loew D; Schuster O
    Eur J Drug Metab Pharmacokinet; 1988; 13(3):161-4. PubMed ID: 3240762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of a combination of a diuretic and nifedipine retard for the treatment of hypertensive patients refractory to nifedipine retard].
    Martínez López JJ; Rúiz López FJ; Gómez Márquez M; Ortega González G; Molina Boix M; Florenciano Sánchez R
    An Med Interna; 1993 Aug; 10(8):386-9. PubMed ID: 8218783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the effects of two modified release preparations of nifedipine-nifedipine retard 10 mg twice daily and nifedipine GITS 20 mg once daily--in the treatment of mild to moderate hypertension.
    Kirby BJ; Kitchin NR
    Int J Clin Pract; 1999; 53(5):339-43. PubMed ID: 10695096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind comparison of amlodipine and nifedipine retard in the treatment of mild to moderate hypertension.
    Lorimer AR; Anderson JA; Laher MS; Davies J; Lazarus JH; Taylor SH; Sanghera S
    J Hum Hypertens; 1994 Jan; 8(1):65-8. PubMed ID: 8151609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Directive clinique n
    Kingdom J; Ashwal E; Lausman A; Liauw J; Soliman N; Figueiro-Filho E; Nash C; Bujold E; Melamed N
    J Obstet Gynaecol Can; 2023 Oct; 45(10):102155. PubMed ID: 37730301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and safety of aranidipine in Chinese patients with mild-to-moderate essential hypertension].
    Jiao Y; Chen L; Zheng JT; Ke YN; Wang Y; Yang HY; Jin H; Zhao XL; Liu MX; Wang L; Wang BY; Li DY
    Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(39):3104-10. PubMed ID: 24417987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of once-daily nifedipine controlled-release with twice-daily nifedipine retard in the treatment of essential hypertension.
    Minami J; Numabe A; Andoh N; Kobayashi N; Horinaka S; Ishimitsu T; Matsuoka H
    Br J Clin Pharmacol; 2004 May; 57(5):632-9. PubMed ID: 15089817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 24-hour blood pressure, heart rate, and autonomic nerve activity in hypertensive patients treated with cilnidipine or nifedipine retard.
    Minami J; Ishimitsu T; Kawano Y; Numabe A; Matsuoka H
    J Cardiovasc Pharmacol; 1998 Aug; 32(2):331-6. PubMed ID: 9700998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of amlodipine and nifedipine retard on autonomic nerve activity in hypertensive patients.
    Minami J; Ishimitsu T; Kawano Y; Matsuoka H
    Clin Exp Pharmacol Physiol; 1998; 25(7-8):572-6. PubMed ID: 9673431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin sensitivity following treatment with the alpha 1-blocker bunazosin retard and the beta 1-blocker atenolol in hypertensive non-insulin-dependent diabetes mellitus patients.
    Eriksson JW; Jansson PA; Foley K; Lithell H
    J Hypertens; 1996 Dec; 14(12):1469-75. PubMed ID: 8986932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of the scientific basis for dentistry and its impact on dental education: past, present, and future.
    Slavkin HC
    J Dent Educ; 2012 Jan; 76(1):28-35. PubMed ID: 22262547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolution of America's scientific advancements in dentistry in the past 150 years.
    Gutmann JL
    J Am Dent Assoc; 2009 Sep; 140 Suppl 1():8S-15S. PubMed ID: 19723925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability and elimination kinetics of the combination furosemide-retard/triamterene.
    Schuster O; Loew D; Knoell HE
    Eur J Drug Metab Pharmacokinet; 1985; 10(2):127-32. PubMed ID: 4043142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of domestic bisoprolol,enalapril and nifedipine retard in mild to moderate hypertension: a randomized double-blind multicenter clinical trial in China.
    Liu G; Li M; Shi X; Et Al
    Zhonghua Nei Ke Za Zhi; 2002 Jul; 41(7):450-2. PubMed ID: 12189112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of the effects of molsidomine retard and isosorbide dinitrate retard in patients with stable angina pectoris using an ergometry test].
    Rotrekl P; Vlasínová J; Manousek J; Semrád B; Rysavý F; Lupínek Z; Meluzín J; Vlasicová I; Pirochtová I; Bocek O
    Vnitr Lek; 1993 Sep; 39(9):856-64. PubMed ID: 8212639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Demonstration of the long term action of an oral retard preparation of verapamil in the conscious dog].
    Raschack M
    Arzneimittelforschung; 1975 Aug; 25(8):1275-8. PubMed ID: 1242358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of conventional and slow release forms of nifedipine in essential hypertensive patients.
    Imai Y; Abe K; Sasaki S; Nihei M; Sekino H; Yoshinaga K
    Tohoku J Exp Med; 1986 Apr; 148(4):421-38. PubMed ID: 3738908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The maturation of science within dentistry: the impact of critical milestones and visionary leaders on contemporary achievements.
    Gutmann JL
    J Hist Dent; 2009; 57(3):109-22. PubMed ID: 20222217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.